Mylan in India

Mylan is one of the world’s leading global pharmaceutical companies, with a significant and growing presence in India. We have a workforce of more than 30,000 people, approximately half of whom are based in India. Our broad portfolio includes generic and brand name products in a variety of dosage forms, which are sold in about 165 countries and territories.

Mylan’s history in India began in 2007 with the acquisition of Matrix Laboratories Limited. The deal transformed Mylan overnight into one the world’s largest manufacturers of active pharmaceutical ingredients (API) and allowed us to vertically integrate the production of our finished dosage form (FDF) medicines.

Today, Mylan’s manufacturing platform includes more than 40 facilities, 25 of which are located in India. Those 25 facilities include all nine of our API facilities and 15 of our FDF facilities, which manufacture our high quality medicines for markets all over the world, including emerging markets. Our manufacturing capabilities in India include a range of dosage forms, such as tablets, capsules and injectables, in a wide variety of therapeutic categories.

Our commercial businesses based in India market hiqh quality API to third parties around the world and antiretroviral products for people living with HIV/AIDS. Today, nearly 50% of those receiving treatment for the disease in the developing world rely on a Mylan product, all of which are made by us in India. In fact, Mylan is India’s third largest pharmaceutical exporter.

In addition, Mylan has a growing commercial presence domestically. Our current franchises include Critical Care, Hepato Care, HIV Care, Onco Care and Women’s Care.

Further, our presence in India goes beyond manufacturing, sales and marketing. Hyderabad is home to one of Mylan’s three global R&D centers of excellence. The center has extensive experience working with health authorities from multiple countries. It also is fully integrated with the company’s global R&D function, creating a unique and efficient, ‘round-the-clock research, development, clinical and regulatory capability.


  • Mylan in India at a Glance

    2007: Mylan acquired Matrix Laboratories Limited
    25: Manufacturing facilities
    250+: APIs in pipeline
    > 15,000: Workforce
    ~ 1,500: Scientific Affairs workforce
    400+: India domestic sales representatives 

    Fact Sheet

  • Rakesh Bamzai

    Rakesh Bamzai_

    President, India Commercial and Emerging Markets

    Rakesh Bamzai is president of Mylan’s India Commercial and Emerging Markets. Bamzai has more than 20 years of experience in the Indian and global biopharmaceutical industry and is responsible for growing Mylan’s antiretroviral, third-party active pharmaceutical ingredient (API), generic and specialty businesses in India and in emerging markets. He is based in Hyderabad, India.

    Prior to joining Mylan, he was president of Marketing at Biocon, where he played a key role in building the company's global biopharmaceutical business. He had overall responsibility for API and branded formulations and managed a team of more than 2,000 people across functional areas and geographies. Through the years, he also spearheaded many strategic partnerships that enabled the organization to gain wider global access and greater market penetration for its biopharmaceuticals business. Bamzai also led Biocon's foray into branded formulations and built many successful brands across therapies in India and Gulf Cooperation Council states.

    Bamzai graduated from the University of Mumbai (Department of Chemical Technology).

  • Dr. Haribabu Bodepudi

    Dr. Hari Babu
    Head of Mylan’s Global Oral Solid Dose and Active Pharmaceutical Ingredients Operations

    Dr. Haribabu Bodepudi is the head of Mylan’s Global Oral Solid Dose (OSD) and Active Pharmaceutical Ingredients (API) Operations. Dr. Bodepudi oversees all of Mylan’s OSD and API manufacturing sites across the world. He is based in Hyderabad, India.

    Dr. Bodepudi has more than 21 years of pharmaceutical experience in various functions and of increasing responsibility, including R&D, manufacturing, regulatory and quality. His current responsibility as head of Mylan’s Global OSD and API Operations is the management and effective utilization of manufacturing capacity and delivering high quality products to the more than 165 countries and territories we serve around the world. Prior to taking over as head of global OSD and API, Dr. Bodepudi was the managing director and CEO of Mylan Laboratories Limited and oversaw the OSD and API manufacturing within India and was responsible for Mylan’s ARV businesses.

    Dr. Bodepudi earned his Ph.D. from Andhra University and has a number of national and international publications to his credit. He also filed for several patents during his tenure in the industry.

  • Sanjeev Sethi

    Head of Mylan’s Global Injectable Operations

    Sanjeev Sethi is Mylan’s head of Global Injectable Operations and is based in Bangalore, India.

    Sethi led Mylan’s integration activities of Agila Specialty’s global injectables franchise, which was acquired from Strides Arcolab Limited in 2013. He currently oversees all of Mylan’s injectables manufacturing around the world.

    Sethi has more than 25 years of experience in pharmaceuticals. He joined Mylan when the company acquired Matrix Laboratories in January 2007. He had been with Matrix since 2005 and was responsible for the company’s Technical Operations of Finished Dosage Forms (FDF).

    Subsequently, Sethi played a vital role in building Mylan’s teams and infrastructure for R&D, Regulatory Affairs, Quality Management and Commercial Manufacturing of finished doses. Under his leadership, several products were developed and commercialized, including the company’s flagship portfolio of antiretroviral (ARV) finished doses, which are used in the treatment of HIV/AIDS.

    Prior to his current position, Sethi was Mylan’s global head of Scientific Affairs, which included leadership of Portfolio Management, R&D, Regulatory Affairs and Launch Management. While in this role, he helped design and build the Scientific Affairs organization as part of the Mylan-Matrix-Merck Generics integration.

    He also has held senior positions at other major pharmaceutical companies, including Ranbaxy and Sandoz, in the areas of Formulations Development and Regulatory Affairs.

    Sethi has a post-graduate degree in pharmaceutical sciences from Punjab University and 40 international patents to his credit.